Global Late-Stage Chronic Kidney Disease Therapeutics Market to Surpass at a remarkable CAGR of 11.6% from 2022 to 2032 Amid Rising CKD Prevalence | FMI

The global late-stage chronic kidney disease therapeutics market is witnessing significant growth, driven by the increasing prevalence of chronic kidney disease worldwide. Valued at approximately USD 4.7 billion in 2019, the market is set to surpass USD 11.1 billion by 2027, expanding at a remarkable CAGR of 11.6% from 2022 to 2032.

CKD has emerged as a critical public health challenge due to its high morbidity and mortality rates. The disease is primarily caused by diabetes mellitus, hypertension, obesity, and aging—all of which are rising at an alarming rate globally. As CKD progresses into its late stage, kidney function declines significantly, leading to life-threatening complications. This necessitates the need for effective treatment strategies such as kidney transplants, dialysis, and therapeutic drugs.

Discover How Market Trends Are Shaping Industries: Access Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d39313935

Rising Need for Late Stage CKD Therapeutics Amid Treatment Limitations

The late-stage chronic kidney disease market has gained significant traction due to the limitations of existing treatments. While kidney transplantation and dialysis are considered the most effective treatments for late-stage CKD, both come with significant challenges. Dialysis is expensive and requires continuous management, while kidney transplants face a global organ shortage, leaving many patients without viable options.

In this scenario, late-stage CKD therapeutics play a crucial role in managing symptoms and improving patient survival rates. These therapeutics are particularly essential for patients with lower socioeconomic status who have limited access to dialysis or transplants. Moreover, they are often used in combination with dialysis, helping to relieve symptoms and delay disease progression.

Role of Therapeutics in Managing Late-Stage CKD

Late-stage chronic kidney disease therapeutics primarily focus on treating CKD-induced complications such as:

• Hyperkalemia (elevated potassium levels)
• Hyperphosphatemia (excess phosphate in the blood)
• Hyperparathyroidism (parathyroid gland dysfunction)

By effectively managing these conditions, these therapeutics help to:

• Reduce CKD symptoms
• Delay disease progression
• Enhance patient survival rates
• Improve quality of life without dialysis or transplants

Market Growth Driven by Increasing CKD Cases & R&D Advancements

The demand for late-stage CKD therapeutics is being propelled by rising CKD prevalence worldwide. According to health reports, CKD affects over 850 million people globally, with millions progressing to late-stage renal failure each year. Sedentary lifestyles, unhealthy diets, and the growing aging population are further exacerbating the problem, necessitating the development of advanced therapeutic solutions.

Pharmaceutical companies and researchers are actively investing in drug innovations to improve treatment outcomes. Several late-stage CKD therapeutics are being developed to target disease complications more effectively, reducing dependence on dialysis and transplants.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report! https://www.futuremarketinsights.com/reports/late-stage-chronic-kidney-disease-therapeutics-market

Key Takeaways

• North America’s Dominance: North America held the largest share of the global late-stage chronic kidney disease therapeutics market in 2021 and is expected to grow at the fastest CAGR due to the rising incidence of chronic kidney disease, favorable reimbursement policies, and the presence of leading market players.
• U.S. Market Growth: The United States is a key driver of market expansion, with approximately 37 million people affected by chronic kidney disease, according to the CDC. The availability of advanced therapeutics further fuels demand.
• Asia Pacific Growth Potential: The Asia Pacific market is expected to grow significantly from 2022 to 2032, driven by rising health awareness, increasing prevalence of chronic kidney disease, and supportive government initiatives.
• Opportunities in Developing Nations: Countries like China and India are witnessing a surge in kidney failure cases, creating lucrative opportunities for market growth as their aging populations expand.

Future Outlook: A Surge in Demand for CKD Therapeutics

With the growing need for effective treatment alternatives, the late-stage CKD therapeutics market is poised for significant expansion. The pharmaceutical industry’s focus on developing novel drugs, combined with increasing government initiatives for CKD awareness and treatment access, will further fuel market growth.

As healthcare systems worldwide strive to enhance treatment affordability and accessibility, the demand for effective CKD therapeutics will continue to rise, offering hope to millions suffering from this life-threatening disease.

Market Competition

The global late-stage chronic kidney disease therapeutics market features key players such as Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire, Vifor, and ZS Pharma, among others.

These industry leaders are actively investing in research and development to enhance therapeutic efficacy. Additionally, they are forming strategic partnerships with dialysis centers to expand their market reach and strengthen their competitive position.

Future-Proof Your Healthcare Business with Our Reports! https://www.futuremarketinsights.com/industry-analysis/therapy-area

Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey

By Product Type:

• Calcimimetics
• Sensipar (cinacalcet hydrochloride)
• Vitamin D Sterols
• Nutritional/Native Vitam:in D
• Vitamin D Receptor Agonists
• Phosphate Binders
• Calcium-Based Phosphate Binders
• Aluminum-Containing Phosphate Binders
• Magnesium-Containing Phosphate Binders
• Renvela/Renagel
• Fosrenol (lanthanum carbonate)
• Velphoro (sucroferric oxyhydroxide)
• Auryxia (ferric citrate)
• Potassium Binders
• Resins
• Veltassa (patiromer sorbitex calcium)

By Indication:

• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalemia

By End Users:

• Hospital Pharmacy
• Retail Pharmacy
• Mail Order Pharmacy

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube